Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Durvalumab Approaches EU Approval for Locally Advanced PD-L1+ NSCLC

July 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy and whose tumors express PD-L1 on ≥1% of tumor cells.

Immunotherapy Requires Precision Medicine Approach for NSCLC

July 27th 2018

Immunotherapy should be given as a tailored, not blanket, treatment approach, especially for patients with lung cancer, according to Giorgio Scagliotti, MD, PhD.

Dr. Langer on Practice-Changing PACIFIC Data in Stage III NSCLC

July 27th 2018

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the practice-changing data from the PACIFIC trial, which evaluated durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.

Dr. Bazhenova on Prevalence of NTRK Mutations in NSCLC and Emerging Treatments

July 27th 2018

Lyudmila A. Bazhenova, MD, medical oncologist professor of medicine, University of California, San Diego, discusses the prevalence of NTRK mutations in non–small cell lung cancer.

Targeted Therapy Options Expanding for NSCLC

July 27th 2018

Several novel targeted therapies are emerging for a growing number of driver mutations in lung cancer, with multiple targeted agents now confirmed standards of care.

Dr. Aggarwal on Triplet Therapy in EGFR-Mutant Lung Cancer

July 27th 2018

Charu Aggarwal, MD, assistant professor of Medicine, University of Pennsylvania, discusses triplet therapy in EGFR-mutant lung cancer.

Dr. Bauml on Emerging Biomarkers in NSCLC

July 27th 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses emerging biomarkers in non–small cell lung cancer (NSCLC).

Rationale for Liquid Biopsies in NSCLC

July 26th 2018

Best Practices in Molecular Profiling in NSCLC

July 26th 2018

Significance of Next-Generation Sequencing in NSCLC

July 26th 2018

Treating Rare Actionable Mutations in NSCLC

July 26th 2018

Combination Therapy in BRAF-Mutant NSCLC

July 26th 2018

Treatment Considerations in ALK/ROS-1 Rearranged NSCLC

July 26th 2018

Managing Resistance to ALK Inhibitors in NSCLC

July 26th 2018

Treating ALK-Mutated NSCLC With Disease Progression

July 26th 2018

Alectinib in ALK-Mutated NSCLC

July 26th 2018

Emerging Therapies in EGFR-Positive NSCLC

July 26th 2018

EGFR TKIs as Adjuvant Therapy in NSCLC

July 26th 2018

Afatinib Therapy for Uncommon EGFR Alterations in NSCLC

July 26th 2018

Managing Resistance to EGFR TKIs in NSCLC

July 26th 2018